Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England) · 2024 · 69 citations · Christopher Tait
Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience.
Inflammatory bowel diseases · 2025 · 21 citations · Gabriele Meyer
The Brain-Gut-Microbiotal Axis: A framework for understanding functional GI illness and their therapeutic interventions.
European journal of internal medicine · 2021 · 57 citations · Christopher Tait
Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment.
Journal of clinical and translational hepatology · 2023 · 33 citations · Toni Chandler
Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders.
Gastro hep advances · 2022 · 42 citations · Christopher Tait
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 30 citations ·
Acute kidney injury and hepatorenal syndrome in cirrhosis.
World journal of gastroenterology · 2021 · 48 citations · Christopher Tait
Symptoms classically attributed to laryngopharyngeal reflux correlate poorly with pharyngeal reflux events on multichannel intraluminal impedance testing.
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022 · 22 citations · Sanjay Salgado